xylometazoline hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
xylometazoline hydrochloride: clinical details
Prescribing considerations
- Confirm the exact product, device and age restriction because selected sprays and drops are not interchangeable.
- Assess concurrent decongestants and medicines with sympathomimetic or cardiovascular interactions.
- Consider cardiovascular disease, hypertension, diabetes, hyperthyroidism, occlusive vascular disease, prostatic enlargement and exaggerated sympathomimetic responses.
- Long-QT syndrome may increase susceptibility to serious ventricular arrhythmias.
- Persistent or escalating use may indicate rebound congestion or rhinitis medicamentosa.
- Benzalkonium chloride can irritate or swell the nasal mucosa, particularly with extended exposure.
Contraindications and cautions
- Hypersensitivity to xylometazoline or product excipients.
- Trans-sphenoidal hypophysectomy or surgery exposing the dura mater.
- Selected products: narrow- or closed-angle glaucoma, rhinitis sicca or atrophic rhinitis, phaeochromocytoma, prostatic hypertrophy and current or recent MAOI use.
- Age restrictions are formulation-specific.
- Some selected product information additionally contraindicates cardiovascular disease, hypertension, diabetes, hyperthyroidism, beta-blockers or other sympathomimetic decongestants.
Monitoring
- Review worsening congestion, reduced response, persistent nasal irritation or visible mucosal change as possible overuse effects.
- In susceptible patients, monitor for hypertension, tachycardia, arrhythmia, tremor, insomnia or dizziness.
- In children or suspected overuse, assess promptly for agitation, hallucinations, altered consciousness or cardiorespiratory toxicity.
Clinical pharmacology
A locally applied imidazoline sympathomimetic that directly stimulates alpha-adrenoceptors, causing nasal vasoconstriction and decongestion. Systemic absorption is usually limited but can occur, particularly with excessive exposure or ingestion.
Formulation and product differences
- Selected products include nasal drops and metered sprays with different pump-priming instructions.
- Child drops have a distinct age range and a broader contraindication and interaction list than some adult products.
- Selected formulations contain benzalkonium chloride; excipient quantities, bottle designs, storage and in-use shelf lives differ.
- Licensed indications vary slightly between products.
xylometazoline hydrochloride preparations and strengths
Nasal preparation
Route: Nasal
Strengths: 0.1%, 0.1% w/v
xylometazoline hydrochloride interactions
Clinically important sympathomimetic interactions are possible, and restrictions differ between products.
Other sympathomimetic decongestants, including pseudoephedrine, phenylephrine, ephedrine or oxymetazoline
Do not combine oral or nasal decongestants because duplicate sympathomimetic effects increase the risk of harm.
Monoamine oxidase inhibitors, including moclobemide
Concurrent or recent use can dangerously raise blood pressure and is contraindicated in selected products.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.